IBRX stock trades at $9.55 pre-market as ImmunityBio, Inc. (NASDAQ: IBRX) prepares to release fiscal Q4 and full-year 2025 results on Mar 3, 2026. Investors will focus on clinical progress for ANKTIVA and other pipeline programs, plus cash burn and guidance. Volume is elevated at 37,880,600.00 versus an average of 34,049,421.00, signaling heavy interest. This earnings spotlight reviews what the report must show to justify the recent run, and which metrics could drive intraday moves in the United States market

IBRX stock: earnings timing and what to expect

ImmunityBio will host a business update and FY2025 review on Mar 3, 2026 at 13:30 PT. The company confirmed the event in a Business Wire release; investors can follow the call on the company site source. One clear expectation is detail on trial enrollment and any ANKTIVA safety or efficacy signals. Another expectation is updated cash runway and R&D pacing to fund Phase II/III work.

Key numbers shareholders will watch in the report

Market focus will land on cash position, revenue trends, and guidance for 2026. Current headline metrics include price $9.55, EPS -0.41, and PE -23.85. Investors will also parse R&D spend and operating cash flow given a free cash flow per share of -0.31. Expect management to address working capital and funding options if required.

Valuation and analyst setup for IBRX stock

ImmunityBio shows extreme valuation multiples driven by a small revenue base and large market cap. Price-to-sales is 82.81, EV/sales is 89.79, and book value per share is -0.50. Street coverage skews bullish: the upgrade/downgrade table shows 9 Buy calls and no Holds or Sells. With no consensus price target published, scenario targets could be conservative $5.00, base $10.00, and bull $15.00 per share as working guideposts for risk management.

Technical and trading setup for IBRX stock

Technicals show strong momentum ahead of the report. RSI is 66.11 and ADX is 53.37, indicating a strong trend. The 50-day average is 4.98 and the 200-day average is 3.14, both below today’s price. Intraday range so far is $8.98 to $9.97. Elevated volume at 37,880,600.00 versus average 34,049,421.00 points to higher liquidity and volatility around the release.

Meyka AI rates IBRX with a score out of 100

Meyka AI rates IBRX with a score out of 100: 74.36 / 100, Grade: B+, Suggestion: BUY. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, analyst consensus, and forecast models.

This grade is informational and not investment advice. It highlights strong momentum and heavy analyst Buy sentiment, offset by stretched valuation and negative earnings. For more on filings and the company profile see MarketWatch source.

Meyka AI’s forecast and modeled downside for IBRX stock

Meyka AI’s forecast model projects a 12-month yearly estimate of $2.19 per share. Compared to the current price of $9.55, that implies a modeled downside of -77.06%. Forecasts are model-based projections and not guarantees. Use the projection as a stress-check against management guidance and upcoming clinical readouts.

Final Thoughts

Key takeaways for IBRX stock ahead of the Mar 3, 2026 release: ImmunityBio must show clear clinical progress and a defined cash plan to support ongoing Phase II/III programs. Today’s pre-market price of $9.55 reflects strong momentum but also elevated valuation, with price-to-sales at 82.81 and EV/sales at 89.79. Analyst coverage is tilted positive with 9 Buy calls, yet Meyka AI’s model flags downside risk: Meyka AI’s forecast model projects a 12‑month value of $2.19, implying -77.06% versus current price. That forecast is a model output, not a guarantee, and should be weighed against management guidance, trial milestones, and cash runway disclosures on the call. For investors in the United States on NASDAQ, treat the print as a binary catalyst: strong pipeline news could validate the stock’s run, while weak operational detail or worse-than-expected cash metrics could trigger a sharp pullback. Our coverage uses Meyka AI-powered market analysis platform tools to track live moves and will update immediately after the conference call. Monitor volume and intra-day ranges and compare any guidance to the conservative $5.00, base $10.00, and bull $15.00 price scenarios noted above.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.